Level	Gene	Alterations	Tumor Type	Drugs
R1	KRAS	Oncogenic Mutations	Colorectal Cancer	Cetuximab, Panitumumab
R1	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib
R1	EGFR	Exon 20 insertion	Non-Small Cell Lung Cancer	Gefitinib, Afatinib, Erlotinib
R1	ABL1	T315I	Chronic Myelogenous Leukemia	Imatinib, Bosutinib, Nilotinib, Dasatinib
R1	EGFR	T790M	Non-Small Cell Lung Cancer	Gefitinib, Erlotinib, Afatinib
R1	ABL1	T315I	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib, Imatinib, Bosutinib, Dasatinib
R1	NRAS	Oncogenic Mutations	Colorectal Cancer	Panitumumab, Cetuximab
2	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Sorafenib
2	EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	Erlotinib
2	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Bosutinib
2	BRAF	V600E	Hairy Cell Leukemia	Vemurafenib
2	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib
2	BRCA1	Oncogenic Mutations	Ovarian Cancer	Olaparib
2	BRCA1	Oncogenic Mutations	Peritoneal Serous Carcinoma	Olaparib
2	BRCA1	Oncogenic Mutations	Breast Cancer	Olaparib
2	KIT	Oncogenic Mutations	Melanoma	Imatinib
2	KIT	Oncogenic Mutations	Thymic Tumor	Sunitinib
2	BRAF	V600E	Pilocytic Astrocytoma	Cobimetinib + Vemurafenib, Dabrafenib + Trametinib
2	BRAF	V600	Melanoma	Binimetinib + Encorafenib
2	BRAF	V600E	Ganglioglioma	Vemurafenib + Cobimetinib, Trametinib + Dabrafenib
2	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Ado-Trastuzumab Emtansine
2	BRAF	V600E	Pleomorphic Xanthoastrocytoma	Vemurafenib + Cobimetinib, Trametinib + Dabrafenib
2	BRAF	V600	Melanoma	Vemurafenib + Cobimetinib
2	BRAF	V600	Melanoma	Dabrafenib + Trametinib
2	BRAF	V600	Anaplastic Thyroid Cancer	Trametinib + Dabrafenib
2	CDK4	Amplification	Dedifferentiated Liposarcoma	Abemaciclib, Palbociclib
2	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Dasatinib
2	CDK4	Amplification	Well-Differentiated Liposarcoma	Abemaciclib, Palbociclib
2	ABL1	E255K, E255V, F317C, F317I, F317L, F317V, F359C, F359I, F359V, T315A, Y253H	B-Lymphoblastic Leukemia/Lymphoma	Bosutinib
2	BRCA1	Oncogenic Mutations	Breast Cancer	Talazoparib
2	BRAF	V600E	Colorectal Cancer	Panitumumab + Encorafenib
2	ABL1	E255K, E255V, F359C, F359I, F359V, Y253H	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib
2	ERBB2	Amplification	Colorectal Cancer	Trastuzumab + Pertuzumab
2	ABL1	E255K, E255V, F317C, F317I, F317L, F317V, F359C, F359I, F359V, T315A, Y253H	Chronic Myelogenous Leukemia	Bosutinib
2	BRCA2	Oncogenic Mutations	Breast Cancer	Olaparib
2	ABL1	F317C, F317I, F317L, F317V, T315A, V299L	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib
2	ABL1	E255K, E255V, F359C, F359I, F359V, Y253H	Chronic Myelogenous Leukemia	Dasatinib
2	ERBB2	Amplification	Colorectal Cancer	Lapatinib + Trastuzumab
2	ABL1	F317C, F317I, F317L, F317V, T315A, V299L	Chronic Myelogenous Leukemia	Nilotinib
2	ERBB2	Amplification	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	Carboplatin-Taxol Regimen + Trastuzumab
2	PDGFRA	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Imatinib
2	BRCA2	Oncogenic Mutations	Ovarian Cancer	Olaparib
2	MET	D1010, Exon 14 Deletion, Exon 14 splice mutation, Y1003	Non-Small Cell Lung Cancer	Crizotinib
2	MET	Amplification	Non-Small Cell Lung Cancer	Crizotinib
2	RET	Fusions	Non-Small Cell Lung Cancer	Vandetanib
2	BRCA2	Oncogenic Mutations	Peritoneal Serous Carcinoma	Olaparib
2	RET	Fusions	Non-Small Cell Lung Cancer	Cabozantinib
2	MET	Amplification	Renal Cell Carcinoma	Cabozantinib
2	BRCA2	Oncogenic Mutations	Breast Cancer	Talazoparib
2	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Ceritinib
2	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Crizotinib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Imatinib
1	IDH2	Oncogenic Mutations	Acute Myeloid Leukemia	Enasidenib
1	ALK	Oncogenic Mutations	Non-Small Cell Lung Cancer	Brigatinib
1	ABL1	T315I	Chronic Myelogenous Leukemia	Ponatinib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Regorafenib
1	ABL1	T315I	B-Lymphoblastic Leukemia/Lymphoma	Ponatinib
1	FGFR2	Fusions	Bladder Cancer	Erdafitinib
1	EZH2	A682G, A692V, Y646C, Y646F, Y646H, Y646N, Y646S	Follicular Lymphoma	Tazemetostat
1	SMARCB1	Deletion	Epithelioid Sarcoma	Tazemetostat
1	NF1	Oncogenic Mutations	Neurofibroma	Selumetinib
1	PDGFRB	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib
1	BRCA1	Oncogenic Mutations	Ovarian Cancer	Niraparib
1	BRCA1	Oncogenic Mutations	Peritoneal Serous Carcinoma	Niraparib
1	BRAF	V600E	Colorectal Cancer	Cetuximab + Encorafenib
1	NTRK1	Fusions	All Solid Tumors	Entrectinib
1	NTRK1	Fusions	All Solid Tumors	Larotrectinib
1	EGFR	T790M	Non-Small Cell Lung Cancer	Osimertinib
1	TSC1	Oncogenic Mutations	CNS Cancer	Everolimus
1	BRCA1	Oncogenic Mutations	Ovarian Cancer	Rucaparib
1	EGFR	Exon 19 deletion, L858R	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	Exon 19 deletion, L858R	Non-Small Cell Lung Cancer	Erlotinib
1	EGFR	Exon 19 deletion, L858R	Non-Small Cell Lung Cancer	Osimertinib
1	EGFR	Exon 19 deletion, L858R	Non-Small Cell Lung Cancer	Gefitinib
1	EGFR	Exon 19 deletion, L858R	Non-Small Cell Lung Cancer	Dacomitinib
1	BRCA1	Oncogenic Mutations	Peritoneal Serous Carcinoma	Rucaparib
1	KRAS	Wildtype	Colorectal Cancer	Cetuximab
1	PDGFRA	D842V, D842Y, D842_H845del, D842_H845insV	Gastrointestinal Stromal Tumor	Avapritinib
1	KRAS	Wildtype	Colorectal Cancer	Regorafenib
1	KRAS	Wildtype	Colorectal Cancer	Panitumumab
1	PDGFB	COL1A1-PDGFB Fusion	Dermatofibrosarcoma Protuberans	Imatinib
1	TSC2	Oncogenic Mutations	CNS Cancer	Everolimus
1	NTRK2	Fusions	All Solid Tumors	Entrectinib
1	NTRK2	Fusions	All Solid Tumors	Larotrectinib
1	EGFR	S768I	Non-Small Cell Lung Cancer	Afatinib
1	BRAF	V600E	Melanoma	Vemurafenib
1	EGFR	L861Q	Non-Small Cell Lung Cancer	Afatinib
1	BRAF	V600E	Melanoma	Dabrafenib
1	BRAF	V600E	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib
1	BRAF	V600E	Anaplastic Thyroid Cancer	Dabrafenib + Trametinib
1	FGFR2	Fusions	Cholangiocarcinoma	Pemigatinib
1	FLT3	D835, I836, Internal tandem duplication	Acute Myeloid Leukemia	Gilteritinib
1	NTRK3	Fusions	All Solid Tumors	Entrectinib
1	NTRK3	Fusions	All Solid Tumors	Larotrectinib
1	ERBB2	Amplification	Breast Cancer	Trastuzumab Deruxtecan
1	ERBB2	Amplification	Breast Cancer	Tucatinib + Capecitabine + Trastuzumab
1	BRAF	V600	Erdheim-Chester Disease	Vemurafenib
1	MET	D1010, Exon 14 Deletion, Exon 14 splice mutation, Y1003	Non-Small Cell Lung Cancer	Capmatinib
1	BRAF	V600E, V600K	Melanoma	Trametinib + Dabrafenib
1	BRAF	V600E, V600K	Melanoma	Vemurafenib + Cobimetinib
1	BRAF	V600E, V600K	Melanoma	Trametinib
1	RET	Oncogenic Mutations	Medullary Thyroid Cancer	Selpercatinib
1	BRAF	V600E, V600K	Melanoma	Encorafenib + Binimetinib
1	BRCA2	Oncogenic Mutations	Ovarian Cancer	Rucaparib
1	RET	Fusions	Non-Small Cell Lung Cancer	Selpercatinib
1	BRCA2	Oncogenic Mutations	Ovarian Cancer	Niraparib
1	RET	Fusions	Thyroid Cancer	Selpercatinib
1	BRCA2	Oncogenic Mutations	Peritoneal Serous Carcinoma	Niraparib
1	IDH1	Oncogenic Mutations	Acute Myeloid Leukemia	Ivosidenib
1	BRCA2	Oncogenic Mutations	Peritoneal Serous Carcinoma	Rucaparib
1	ATM	Oncogenic Mutations	Prostate Cancer	Olaparib
1	BARD1	Oncogenic Mutations	Prostate Cancer	Olaparib
1	BRIP1	Oncogenic Mutations	Prostate Cancer	Olaparib
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Imatinib
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Ponatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Imatinib
1	PIK3CA	Oncogenic Mutations	Breast Cancer	Alpelisib + Fulvestrant
1	CHEK1	Oncogenic Mutations	Prostate Cancer	Olaparib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Dasatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Nilotinib
1	CHEK2	Oncogenic Mutations	Prostate Cancer	Olaparib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Bosutinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Entrectinib
1	PALB2	Oncogenic Mutations	Prostate Cancer	Olaparib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	RAD51B	Oncogenic Mutations	Prostate Cancer	Olaparib
1	RAD51C	Oncogenic Mutations	Prostate Cancer	Olaparib
1	RAD51D	Oncogenic Mutations	Prostate Cancer	Olaparib
1	RAD54L	Oncogenic Mutations	Prostate Cancer	Olaparib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Sunitinib
1	BRCA1	Oncogenic Mutations	Prostate Cancer	Rucaparib
1	ERBB2	Amplification	Breast Cancer	Ado-Trastuzumab Emtansine
1	PDGFRA	FIP1L1-PDGFRA Fusion	Chronic Eosinophilic Leukemia, NOS	Imatinib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Imatinib
1	ERBB2	Amplification	Breast Cancer	Trastuzumab
1	Other Biomarkers	Microsatellite Instability-High	Colorectal Cancer	Nivolumab
1	ERBB2	Amplification	Breast Cancer	Pertuzumab + Trastuzumab
1	FLT3	Oncogenic Mutations	Acute Myeloid Leukemia	Midostaurin + High Dose Chemotherapy
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Regorafenib
1	BRCA1	Oncogenic Mutations	Prostate Cancer	Olaparib
1	ERBB2	Amplification	Breast Cancer	Lapatinib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 deletion, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Imatinib
1	BRCA2	Oncogenic Mutations	Prostate Cancer	Olaparib
1	ERBB2	Amplification	Breast Cancer	Neratinib
1	Other Biomarkers	Microsatellite Instability-High	Colorectal Cancer	Ipilimumab + Nivolumab
1	BRCA2	Oncogenic Mutations	Prostate Cancer	Rucaparib
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Lapatinib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 deletion, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Regorafenib
1	ERBB2	Amplification	Esophagogastric Cancer	Trastuzumab
1	Other Biomarkers	Microsatellite Instability-High	All Solid Tumors	Pembrolizumab
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 deletion, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Sunitinib
1	PDGFRA	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib
1	CDK12	Oncogenic Mutations	Prostate Cancer	Olaparib
1	FGFR3	Fusions	Bladder Cancer	Erdafitinib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Sunitinib
1	FANCL	Oncogenic Mutations	Prostate Cancer	Olaparib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Imatinib
1	FGFR3	G370C, R248C, S249C, Y373C	Bladder Cancer	Erdafitinib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Regorafenib
1	EGFR	G719	Non-Small Cell Lung Cancer	Afatinib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Sunitinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Ceritinib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Imatinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Alectinib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Regorafenib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Sunitinib
1	ALK	Oncogenic Mutations	Non-Small Cell Lung Cancer	Lorlatinib
3	KIT	D816	Mastocytosis	Avapritinib
3	FGFR2	Fusions	Bladder Cancer	AZD4547, Debio1347, BGJ398
3	FGFR2	Fusions	Cholangiocarcinoma	BGJ398, AZD4547, Erdafitinib, Debio1347
3	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Afatinib
3	BRAF	Oncogenic Mutations	Histiocytosis	Cobimetinib
3	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Crenolanib
3	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Sorafenib
3	EGFR	Exon 20 insertion	Non-Small Cell Lung Cancer	Poziotinib
3	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Quizartinib
3	AKT1	E17K	Breast Cancer	AZD5363
3	PTCH1	Truncating Mutations	Skin Cancer, Non-Melanoma	Sonidegib
3	AKT1	E17K	Endometrial Cancer	AZD5363
3	PTCH1	Truncating Mutations	Skin Cancer, Non-Melanoma	Vismodegib
3	AKT1	E17K	Ovarian Cancer	AZD5363
3	PTCH1	Truncating Mutations	Embryonal Tumor	Sonidegib
3	MAP2K2	Oncogenic Mutations	Histiocytosis	Cobimetinib
3	MTOR	L1460P, L2209V, L2427Q	Renal Cell Carcinoma	Temsirolimus
3	MTOR	E2014K, E2419K	Bladder Cancer	Everolimus
3	FGFR1	Amplification	Lung Squamous Cell Carcinoma	BGJ398, Erdafitinib, AZD4547, Debio1347
3	MTOR	Q2223K	Renal Cell Carcinoma	Everolimus
3	RET	Oncogenic Mutations	Medullary Thyroid Cancer	BLU-667
3	RET	Oncogenic Mutations	Medullary Thyroid Cancer	Selpercatinib
3	MET	D1010, Exon 14 Deletion, Exon 14 splice mutation, Y1003	Non-Small Cell Lung Cancer	Cabozantinib
3	HRAS	Oncogenic Mutations	Head and Neck Squamous Cell Carcinoma	Tipifarnib
3	RET	Fusions	Non-Small Cell Lung Cancer	BLU-667
3	ERCC2	Oncogenic Mutations	Bladder Cancer	Cisplatin
3	BRAF	L597	Melanoma	Trametinib
3	IDH1	Oncogenic Mutations	Cholangiocarcinoma	Ivosidenib
3	BRCA2	Oncogenic Mutations	Pancreatic Adenocarcinoma	Rucaparib
3	BRAF	K601	Melanoma	Trametinib
3	MAP2K1	Oncogenic Mutations	Non-Small Cell Lung Cancer	Trametinib, Cobimetinib
3	MAP2K1	Oncogenic Mutations	Melanoma	Cobimetinib, Trametinib
3	MAP2K1	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	MAP2K1	Oncogenic Mutations	Low-Grade Serous Ovarian Cancer	Trametinib, Cobimetinib
3	PIK3CA	Oncogenic Mutations	Breast Cancer	GDC-0077
3	MDM2	Amplification	Liposarcoma	RO5045337
3	PIK3CA	Oncogenic Mutations	Breast Cancer	Copanlisib + Fulvestrant
3	KRAS	Oncogenic Mutations	Histiocytosis	Cobimetinib
3	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Asciminib
3	EGFR	E709_T710delinsD	Non-Small Cell Lung Cancer	Afatinib
3	NRAS	Oncogenic Mutations	Melanoma	Binimetinib + Ribociclib
3	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Neratinib
3	NRAS	Oncogenic Mutations	Melanoma	Binimetinib
3	NRAS	Oncogenic Mutations	Thyroid Cancer	Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol + Selumetinib
3	ERBB2	Oncogenic Mutations	Breast Cancer	Neratinib
3	JAK2	PCM1-JAK2 Fusion	Chronic Eosinophilic Leukemia, NOS	Ruxolitinib
3	KRAS	G12C	Non-Small Cell Lung Cancer	AMG-510
3	EGFR	Exon 19 insertion	Non-Small Cell Lung Cancer	Erlotinib
3	EGFR	Exon 19 insertion	Non-Small Cell Lung Cancer	Gefitinib
3	NRAS	Oncogenic Mutations	Histiocytosis	Cobimetinib
3	FGFR3	Fusions	Bladder Cancer	Debio1347, AZD4547, BGJ398
3	FGFR3	G380R, K650, S371C	Bladder Cancer	AZD4547, BGJ398, Debio1347, Erdafitinib
3	ESR1	Oncogenic Mutations	Breast Cancer	Fulvestrant, AZD9496
3	FGFR3	G370C, R248C, S249C, Y373C	Bladder Cancer	AZD4547, BGJ398, Debio1347
3	BRAF	Fusions	Ovarian Cancer	Cobimetinib, Trametinib
3	ARAF	Oncogenic Mutations	Non-Small Cell Lung Cancer	Sorafenib
3	BRAF	Fusions	Melanoma	Cobimetinib, Trametinib
3	ARAF	Oncogenic Mutations	Histiocytosis	Sorafenib
3	MDM2	Amplification	Liposarcoma	Milademetan Tosylate
3	ARAF	Oncogenic Mutations	Histiocytosis	Cobimetinib
3	RAF1	Oncogenic Mutations	Histiocytosis	Cobimetinib
R2	KIT	D816	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	D816	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	D820	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	D820	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	N822	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	A829P	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	N822	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	A829P	Gastrointestinal Stromal Tumor	Sunitinib
R2	MET	D1228N	Non-Small Cell Lung Cancer	Crizotinib, Capmatinib, Cabozantinib
R2	ALK	C1156Y	Non-Small Cell Lung Cancer	Crizotinib
R2	NTRK3	G623R	All Solid Tumors	Larotrectinib
R2	EGFR	C797S	Non-Small Cell Lung Cancer	Osimertinib
R2	EGFR	L718V	Non-Small Cell Lung Cancer	Osimertinib
R2	MET	Y1230H	Non-Small Cell Lung Cancer	Capmatinib, Crizotinib
R2	ALK	G1202R	Non-Small Cell Lung Cancer	Alectinib
R2	EGFR	C797G	Non-Small Cell Lung Cancer	Osimertinib
R2	EGFR	D761Y	Non-Small Cell Lung Cancer	Gefitinib
R2	ALK	G1269A	Non-Small Cell Lung Cancer	Crizotinib
R2	KIT	Y823D	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	Y823D	Gastrointestinal Stromal Tumor	Imatinib
R2	ALK	I1171N	Non-Small Cell Lung Cancer	Alectinib
R2	KIT	C809G	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	C809G	Gastrointestinal Stromal Tumor	Imatinib
R2	ALK	L1196M	Non-Small Cell Lung Cancer	Crizotinib
R2	KIT	V654A	Gastrointestinal Stromal Tumor	Imatinib
R2	MET	Amplification	Non-Small Cell Lung Cancer	Erlotinib, Gefitinib, Osimertinib
R2	NTRK1	G595R	All Solid Tumors	Larotrectinib
R2	KIT	T670I	Gastrointestinal Stromal Tumor	Imatinib
4	FLI1	EWSR1-FLI1 Fusion	Ewing Sarcoma of Soft Tissue	TK216
4	CDK12	Truncating Mutations	All Solid Tumors	Pembrolizumab, Cemiplimab, Nivolumab
4	PTEN	Oncogenic Mutations	All Solid Tumors	GSK2636771, AZD8186
4	EGFR	L747P	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	Afatinib
4	U2AF1	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	KRAS	Oncogenic Mutations	All Solid Tumors	Cobimetinib, Trametinib, Binimetinib
4	U2AF1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Erlotinib
4	CDKN2A	Oncogenic Mutations	All Solid Tumors	Ribociclib, Palbociclib, Abemaciclib
4	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Gefitinib
4	FGFR2	Oncogenic Mutations	All Solid Tumors	Debio1347, AZD4547, BGJ398, Erdafitinib
4	U2AF1	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	EGFR	Amplification	Glioma	Lapatinib
4	BRAF	G464, G469A, G469R, G469V	All Solid Tumors	PLX8394
4	SRSF2	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	SRSF2	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	EGFR	L718V	Non-Small Cell Lung Cancer	Afatinib
4	SRSF2	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	KDM6A	Oncogenic Mutations	Bladder Cancer	Tazemetostat
4	MTOR	Oncogenic Mutations	All Solid Tumors	Everolimus, Temsirolimus
4	SMARCB1	Oncogenic Mutations	All Liquid Tumors	Tazemetostat
4	EGFR	Exon 19 insertion	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	D761Y	Non-Small Cell Lung Cancer	Osimertinib
4	EGFR	A289V, R108K, T263P	Glioma	Lapatinib
4	FGFR1	Oncogenic Mutations	All Solid Tumors	BGJ398, Erdafitinib, AZD4547, Debio1347
4	SF3B1	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	ZRSR2	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	SF3B1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	ZRSR2	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	FGFR3	Oncogenic Mutations	All Solid Tumors	AZD4547, Erdafitinib, BGJ398, Debio1347
4	SF3B1	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	NF1	Oncogenic Mutations	All Solid Tumors	Trametinib, Cobimetinib
4	ZRSR2	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	BRAF	L597	All Solid Tumors	PLX8394
4	BRAF	K601	All Solid Tumors	PLX8394
4	FLI1	EWSR1-FLI1 Fusion	Ewing Sarcoma	TK216
4	MET	Fusions	All Solid Tumors	Crizotinib